Trials / Unknown
UnknownNCT06174935
Low Dose Atropine for Symptomatic Vitreous Floaters
Low Dose Atropine For Symptomatic Vitreous Floaters
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- Sponsor
- Jeanette Du · Academic / Other
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to identify a potential pharmacologic option by assessing whether 0.01% atropine may be effective for treating bothersome floaters as measured by scores on a modified NEI VFQ-25.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 0.01% atropine ophthalmic drop | 0.01% atropine ophthalmic drop will be applied daily to the affected eye |
Timeline
- Start date
- 2024-01-01
- Primary completion
- 2024-06-01
- Completion
- 2024-06-01
- First posted
- 2023-12-18
- Last updated
- 2023-12-18
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06174935. Inclusion in this directory is not an endorsement.